Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| But all-in-all, we are pleased with the results side of the business and the team performed well |
| We believe that this merger will create a leading global musculoskeletal company that is well positioned for growth and success in the years ahead |
| And we get asked the question, a fair bit around, are you getting paid? Are you worried about your DSOs, things like that, and our cash flow in the first quarter was really strong, which is coming in right on time, if you will, because we've got the $450 million convert coming up |
| What I would say is, look, we are really pleased with the results in the first quarter |
| Our company's performance reflects increased procedure volumes and continued surge in demand for our innovative portfolio |
| In particular, our US business had a strong quarter, including approximately 9% growth and US funnel hardware led by thoracolumbar and more than 20% growth from cervical for the sixth straight quarter |
| But the good news is, as you said it there's we still have a strong pipeline |
| As the leader in lateral with more than 500 peer reviewed publications and more than 60 products launched, XLIF continues to demonstrate superior and more predictable outcomes than traditional spinal fusion procedures |
| And so when you put these two companies together, I mean, you're talking a two plus billion dollar entity, generating the profit margins, that Globus has done a really great job at delivering |
| Yes, we're very proud of how the organization handled what has been, anytime you have a change that we've been talking about, you're going to have some level of distraction |
| Our innovation gives us a strong competitive position to extend our leadership in anterior and take share in segments where we historically have been underrepresented |
| So I think you are seeing some underlying strength in the market, from a volume perspective from some level of pent-up demand |
| In Cervical, our C360 portfolio continues to deliver well above market growth |
| Not only has the Simplify Cervical Disc consistently performed, but we saw impressive year-over-year growth in the entire C360 portfolio |
| The launch of Reline Cervical is driving double digit growth within the posterior cervical fusion subsegment, the additional occipital system enhancement has been receiving positive feedback since its launch in the fourth quarter of 2022 |
| The strength on the top line was impressive |
| But we definitely plan on doing better than what we did in the first quarter |
| But I would say based on the results, I think the team's doing a really nice job, biting through the distraction and really staying focused on things that we can control |
| The next system level software release for Pulse has received positive feedback from our initial sites, giving surgeons and their OR teams enhanced line of sight for navigation, new instrument compatibility, improved remote support and services, and a further streamline OR team experience |
| Our cervical business achieves net sales growth of greater than 20% for the sixth consecutive quarter, led by the C360 portfolio, specifically the Simplify Cervical Disc |
| And with the support of more than 100 peer reviewed studies, the business is well positioned for long term growth |
| But for now, it's been a strong performer for us for the last couple quarters |
| The NuVasive Clinical Services grew nicely, primarily driven by higher case volumes |
| I know, we had a BEAT and up income and EPS, I'd say the primary driver of that was the strength in the top line, to your point earlier |
| Matt Harbaugh Yes, I would just highlight too, hardware was really strong, as Chris said in the prepared remarks and one of the questions earlier, so we are really pleased with the performance in the US market specifically |
| As a reminder, this complementary combination expands our reach to surgeons and patients around the world with limited commercial overlap in key [Tech Difficulty] create a comprehensive portfolio of innovative spine and orthopedic technologies, furthers our commitment to meaningful innovation, expands our operational capabilities and creates a strong financial profile and value creation opportunity for our shareholders |
| We remain confident in the future vision of our combined company and the opportunity to provide superior service to our surgeon and hospital partners to advance patient care |
| So if you actually look at our volume growth in Japan, and you sort of factor that in normalized that our international business still growing double digits, so we're excited about the results we continue to see |
| We had a strong start to the year delivering worldwide net sales of $307.7 million in the first quarter, a 5.8% increase as reported, and a 7.7% increase on a constant currency basis |
| We continue to see strong growth in our global business |
| Statement |
|---|
| Wanted that too just on the merger, like we've talked about this Chris, and Matt, over the last couple of months, but just with NuVasive, having 40% share in the lateral segment, there's been some concerns that there would be some regulatory scrutiny there |
| Foreign currency negatively impacted our net sales performance by $5.6 million during the quarter |
| Biologics net sales declined slightly year-over-year due to case mix |
| Free cash flow during the first quarter was negative $33.2 million, compared to negative $26.7 million in the prior year period |
| The ability for the market to rebound I still think it's challenged |
| I think they are trying to push through profitable procedures, their ability to accelerate above and beyond a normal throughput is probably still challenged in many cases |
| I've had a conversation with one of our board members that has participated on the healthcare side and he was just commenting on the fact the hospitals are still challenged, they've gotten much better, but they're still challenged |
| As a reminder, the first quarter is historically the lowest free cash flow quarter of the year, and typically negative |
| So something we're working on, it was a little bit softer quarter than I would expect it in biologics compared to what we did with the rest of the portfolio |
| Non-GAAP operating margin during the first quarter of 2023 was 11.3%, a decrease of 40 basis points compared to 11.7% in the prior year period |
| Matt, I think on biologics, I heard you mentioned case mix headwinds |
| The year-over-year decline was primarily driven by an increase in excess and obsolete inventory related reserves |
| So there is going to be some continued pressure there |
| The year-over-year decrease was primarily driven by the decrease in gross margin as discussed earlier |
| Non-GAAP gross margin as a percentage of net sales for the first quarter of 2023 was 71.9%, a decrease of 110 basis points compared to 73% in the prior year period |
| So there's still a bit of a drag in that business that we need to continue to track |
| Is that a reasonable place to be? Or should we be higher given Q1 results? Or how should we think about the backlog? It sounds like there could be kind of a drop off in volumes post Q1, as the backlog is realized |
| That quite frankly lacks a lot of standardization |
| So I guess on that subject, most folks, I think heading into results, were expecting that there would be some amount of distraction, maybe even some attrition because of the announcement |
| It's, I will just say this that it's not overly surprising, and not necessarily unexpected |
Please consider a small donation if you think this website provides you with relevant information